NCT06483672 2024-07-03
LungBrain001
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
Clinical Trials
8 trialsNCT04860700 2024-06-12
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
Peking Union Medical College Hospital
Phase 2 Completed
NCT04197492 2024-01-05
Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas
Huashan Hospital
Phase 2 Unknown
NCT05883085 2023-05-31
A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05133349 2021-11-24
EASOAIPPGL
Nanjing First Hospital, Nanjing Medical University
Phase 2 Unknown
NCT04978753 2021-07-27
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04822805 2021-03-30
A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma
First People's Hospital of Hangzhou
Phase 2 Unknown
NCT04668508 2020-12-16
Anlotinib to Malignant Brainstem Glioma
Zhejiang Cancer Hospital
Phase 2 Unknown